巨细胞关节炎管理的最新情况
Aqil Baig1, Sana Gafoor-Haseeb2, Jay Goldsher3
1St James School of Medicine, A-1, Albert Lake Dr, The Quarter, 2640, Anguilla.
Current neurology and neuroscience reports
|June 24, 2024
概括
巨细胞动脉炎的管理正在发展. 新的免疫抑制药物,包括像托西利祖马布这样的生物药物,正在减少对长期葡萄糖皮质激素的依赖,最大限度地减少副作用.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 血管医学 血管医学
背景情况:
- 巨细胞动脉炎 (GCA) 是一种自身免疫性血管炎,影响中大动脉.
- 它通常影响50岁以上的个人,造成视力丧失和其他缺血并发症的风险.
研究的目的:
- 审查巨细胞动脉炎管理的最新进展.
- 突出新兴的治疗策略和GCA的指导方针更新.
主要方法:
- 审查当前的文献和已发表的指导方针.
- 分析GCA药物治疗的趋势,包括葡萄糖皮质类药物和免疫抑制剂.
主要成果:
- 高剂量的葡萄皮质类药物仍然是新诊断的GCA的主要治疗方法.
- 免疫抑制药物,如甲醇,莱夫卢诺米德和生物药物 (例如,托西利祖马布) 越来越多地被使用.
- 指导方针建议早期引入类固醇节约剂,以减轻长期的葡萄糖皮质醇毒性.
结论:
- GCA的管理正在转向早期整合类固醇节约性免疫抑制剂.
- 针对性治疗,如IL-6抑制剂 (例如,托西利祖马布),可以快速降低葡萄糖皮质体剂量.
- 这些策略旨在改善患者的治疗结果,并减少与长期高剂量类固醇使用相关的不良影响.
相关概念视频
Open Angle Glaucoma: Treatment
427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270


